SECURITIES AND EXCHANGE COMMISSION
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
New Jersey (State or Other Jurisdiction of Incorporation) | 1-6571 (Commission File Number) | 22-1918501 (IRS Employer Identification Number) |
Kenilworth, NJ 07033
(Address of Principal Executive Office)
EXPLANATORY NOTE
Schering-Plough is filing an amendment to its 8-K filed earlier today to furnish, as Exhibit 99.4., a press release issued by The University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit titled “Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe.” The exhibit was omitted from the 8-K filed earlier today due to technical difficulties.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
99.4 Press release dated July 21, 2008 titled “Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe”
By: | /s/ Steven H. Koehler | |||
Steven H. Koehler | ||||
Vice President and Controller |
Exhibit | ||
Number | Description | |
99.4 | Press release dated July, 2008 titled “Independent Analysis of the SEAS, SHARP and IMPROVE-IT studies of Ezetimibe” |